Toenail Fungus Treatment: Oral, Topical & Laser Options

Quick answer: Toenail fungus (onychomycosis) is a fungal infection of the nail plate caused most often by dermatophytes — treated with a stepwise approach based on severity and clinical subtype. Mild cases (under 25% of one nail, no matrix involvement) may respond to prescription topical efinaconazole. Moderate-to-severe cases require oral terbinafine (12 weeks, 70–80% cure rate) — the single most effective available treatment. Laser therapy is a drug-free alternative. Confirming the diagnosis before treating is essential. Call (810) 206-1402.

What Is Toenail Fungus (Onychomycosis)? The Pathophysiology

Onychomycosis is a fungal infection of the nail unit — the nail plate, nail bed, nail matrix, or hyponychium (the seal between nail and toe skin). It is the most common nail disorder in adults, affecting approximately 10% of the general population and rising to nearly 20% in adults over 60. Left untreated, the infection spreads to adjacent nails and to the skin (tinea pedis), and in diabetic or immunocompromised patients can serve as a portal for serious bacterial foot infections.

The pathophysiology follows a predictable invasion pattern. Fungi penetrate the nail unit through the hyponychium or through nail plate microtrauma. Once inside, they digest the nail keratin using keratinase enzymes, producing the characteristic crumbling, subungual debris. The infection stimulates the nail bed epithelium to proliferate — producing the thickened, hyperkeratotic subungual material that pushes the nail plate upward (onycholysis). The deeper the infection penetrates toward the nail matrix, the harder it is to eradicate — because the matrix must grow out a completely new, uninfected nail for true cure to occur.

Causative Organisms: Dermatophytes, Yeasts, and Molds

The identity of the infecting organism matters clinically — it determines which antifungal is most effective:

Dermatophytes (80–90% of cases)

The dermatophyte family — particularly Trichophyton rubrum (responsible for ~70% of all onychomycosis) and T. interdigitale — are keratinophilic fungi that live exclusively in keratinized tissue (nails, skin, hair). They cannot survive in systemic tissue, meaning this is always a superficial infection. T. rubrum produces the classic distal-lateral subungual pattern and responds best to oral terbinafine. T. interdigitale is the primary cause of superficial white onychomycosis and is also terbinafine-sensitive.

Yeasts — Candida Species (5–10% of cases)

Candida albicans and related species typically infect nails through the proximal nail fold, producing paronychia and proximal involvement — often in patients with chronic wet-work exposure (healthcare workers, dishwashers) or immunosuppression. Candida onychomycosis does NOT respond well to terbinafine — itraconazole or fluconazole are preferred agents. Misidentifying a Candida infection as a dermatophyte infection and treating with terbinafine is a common reason treatment fails.

Non-Dermatophyte Molds (NDM) (2–10% of cases)

Molds such as Scopulariopsis brevicaulis, Fusarium species, and Aspergillus species occasionally colonize damaged nails. They are frequently laboratory contaminants rather than true pathogens — two positive cultures from separately collected specimens are required to diagnose NDM onychomycosis. Treatment requires itraconazole (not terbinafine); some NDM species are intrinsically resistant to all available oral agents, making laser or surgical nail avulsion the only options.

Clinical implication: Before treating any toenail fungus with oral medication, nail clippings should be sent for periodic acid-Schiff (PAS) stain and fungal culture — or in-office PCR testing — to confirm the diagnosis and identify the organism. Studies show that 30–40% of nails presumed to have fungal infection on clinical appearance alone test negative for fungi. Treating a psoriatic, traumatized, or otherwise dystrophic nail with antifungals wastes time, money, and carries medication risks.

Clinical Subtypes of Onychomycosis

The infection pattern (subtype) reflects the route of entry and dictates both prognosis and treatment choice:

Distal Lateral Subungual Onychomycosis (DLSO) — Most Common

Fungi enter through the hyponychium (the free edge of the nail) and spread proximally under the nail plate along the nail bed. The nail plate itself is typically invaded from below. Clinically: yellow-brown discoloration and subungual hyperkeratosis beginning at the free edge and advancing toward the matrix. The most common pattern; caused most often by T. rubrum. Responds to oral terbinafine; the proximal extent of infection determines how long the nail must grow out to achieve clinical cure.

Superficial White Onychomycosis (SWO)

Fungi directly invade the dorsal surface of the nail plate — the infection lives on the nail, not under it. Appears as chalky white, powdery patches on the nail surface. Most commonly caused by T. interdigitale on toenails (and T. rubrum on fingernails). The critical distinguishing feature is that the nail surface scrapes off easily. SWO responds well to topical antifungals alone in many cases because the infection has not penetrated to the nail bed.

Proximal Subungual Onychomycosis (PSO)

Fungi enter through the proximal nail fold and invade the nail plate from its underside proximally. Clinically: white or opaque discoloration beginning near the cuticle. This is the rarest pattern in immunocompetent adults but is the most common form in HIV-positive patients — its presence should prompt HIV testing if no other immune explanation exists. Requires aggressive systemic treatment; topicals are inadequate.

Endonyx Onychomycosis

A recently described pattern where the fungus invades the nail plate substance itself without significant subungual hyperkeratosis. The nail appears milky-white without thickening or onycholysis. Caused by T. soudanense and T. violaceum; may not respond to standard terbinafine doses — higher doses or combination therapy may be required.

Total Dystrophic Onychomycosis (TDO)

The end-stage of any of the above subtypes: the entire nail plate is destroyed and replaced by fungal debris and keratotic material. The nail matrix is involved. Hardest to treat; oral antifungals achieve significantly lower cure rates. Surgical nail avulsion followed by prolonged topical therapy is often necessary before oral treatment can reach the matrix adequately.

Symptoms and Severity Grading

• Mild (<25% nail surface): Small white or yellow spot at tip or edge; normal nail texture. Topical agents appropriate.
• Moderate (25–75% nail surface): Yellow-brown discoloration spreading proximally; nail thickening; onycholysis; crumbling free edge. Oral antifungal indicated.
• Severe (>75% nail surface): Dramatically thickened (3–5mm), heavily discolored, crumbling, partially or fully lifted nail. May cause shoe pressure pain. Oral antifungal ± debridement required.
• Total dystrophic: Entire nail plate destroyed. Matrix involved. Combination oral + debridement ± nail avulsion typically required.

Diagnosis — Confirming Fungal Infection Before Treating

Clinical diagnosis alone has 30–40% false-positive rate. Before any antifungal treatment, confirm the diagnosis:

• PAS stain + fungal culture: The traditional standard. PAS stain provides rapid histologic confirmation (within 3–5 days). Culture identifies the organism and guides drug selection but takes 3–6 weeks.
• Nail PCR testing: Now available in-office. Identifies dermatophyte, Candida, and selected NDM species within 24–48 hours with higher sensitivity than culture (~95% vs ~50%). The preferred method at Balance Foot & Ankle for rapid, organism-specific diagnosis.
• KOH preparation: Rapid bedside test — a nail scraping dissolved in potassium hydroxide and examined under microscopy for fungal hyphae. High sensitivity but doesn’t identify the organism.

Differentiating onychomycosis from nail psoriasis, lichen planus, traumatic dystrophy, and yellow nail syndrome is essential — these conditions mimic fungal nail infection and will not respond to antifungals.

Watch Dr. Tom Biernacki DPM explain the top toenail fungus treatments for 2026 — causes, diagnosis, and what actually works at Balance Foot & Ankle.

Onychomycosis vs. Similar Conditions — Differential Diagnosis

• Nail psoriasis: Pitting (stippled depressions in the nail surface), oil-drop sign (salmon-colored spots under the nail), onycholysis, and subungual hyperkeratosis. Up to 50% of psoriasis patients have nail involvement. Negative fungal culture. History of cutaneous psoriasis or psoriatic arthritis.
• Traumatic nail dystrophy: History of toe box trauma or chronic shoe rubbing. Thickening and discoloration without positive fungal studies. Bilateral symmetry common. No subungual crumbling (or minimal).
• Lichen planus of the nail: Thinning, ridging, and splitting of the nail plate (not thickening); pterygium (scarring of the nail fold over the nail plate) is pathognomonic. Biopsy of the nail fold confirms diagnosis.
• Yellow nail syndrome: All nails become yellow, thickened, and slow-growing simultaneously — associated with lymphedema and pleural effusions. Bilateral, symmetric involvement of all nails distinguishes this from onychomycosis. Negative cultures.
• Subungual melanoma: Dark band or diffuse nail discoloration — particularly if the Hutchinson sign (pigmentation of the proximal nail fold) is present. Any pigmented nail lesion in an adult requires dermatoscopic evaluation and possible biopsy.

Treatment Options — The Complete Hierarchy

Step 1: Over-the-Counter Options (Mild/Very Early Infection)

OTC undecylenic acid products (Fungi-Nail, Formula 3) and tea tree oil have limited nail penetration — they may suppress early superficial infection but rarely cure established onychomycosis. Appropriate only for nail surface (SWO) or as prevention. Maximum honest use: 3 months with no improvement = seek professional care.

Step 2: Prescription Topical Antifungals (Mild Infection, No Matrix Involvement)

• Efinaconazole (Jublia) 10% solution: Best nail penetration of any topical; once-daily application × 48 weeks. Complete cure rate 15–18%. Appropriate for mild DLSO or SWO.
• Tavaborole (Kerydin) 5% solution: Boron-based antifungal; 6–9% complete cure at 52 weeks. Best used as maintenance after oral treatment.
• Ciclopirox (Penlac) 8% lacquer: Older agent; 6–8% cure rate. Requires daily application and weekly removal with alcohol. Largely superseded by efinaconazole.

Step 3: Oral Antifungals (Moderate-to-Severe Infection — First-Line for Most Cases)

• Terbinafine (Lamisil) 250mg daily × 12 weeks: First-line for dermatophyte onychomycosis. Inhibits squalene epoxidase — fungicidal rather than fungistatic. 70–80% mycologic cure. Drug persists in the nail for months after treatment ends. Baseline liver function test required; contraindicated in active liver disease.
• Itraconazole (Sporanox) 200mg daily × 12 weeks OR pulse (200mg BID × 1 week/month × 3 months): Preferred for Candida, NDM, or terbinafine-refractory cases. 55–70% mycologic cure. More drug interactions than terbinafine — full medication reconciliation essential. Pulse dosing reduces systemic exposure and cost.
• Fluconazole (Diflucan) 150–300mg weekly × 12–18 months: Off-label but used for Candida onychomycosis and in patients who cannot tolerate other agents. Lower efficacy than terbinafine for dermatophytes.

Step 4: Laser Therapy (Drug-Free Alternative / Adjunct)

Nd:YAG (1064nm) and diode lasers heat fungal elements through the nail plate to temperatures that kill the organism without damaging the surrounding tissue. FDA-cleared for temporary increase in clear nail. Typical protocol: 3–4 monthly sessions. Published mycologic cure rates: 30–60% (varies significantly by study and laser system). Main advantages: no systemic side effects, no liver monitoring, no drug interactions — ideal for patients on multiple medications or with liver compromise. Not covered by most insurance. Best results when combined with topical efinaconazole between sessions.

Step 5: Combination Therapy (Severe or Recurrent Infection)

Oral terbinafine + topical efinaconazole achieves 80–90% cure in severe or recurrent cases. Chemical or surgical nail debridement prior to oral treatment improves drug delivery to the nail bed by removing the thickened keratotic barrier. Total nail avulsion may be indicated for TDO (total dystrophic onychomycosis) where the nail plate has been fully destroyed — removal exposes the nail bed directly to topical therapy.

Most Common Treatment Mistakes

• Treating without confirming the diagnosis: Nearly one-third of presumed fungal nails are actually psoriatic, traumatic, or otherwise dystrophic — and will not respond to antifungals. Always confirm with culture or PCR first.
• Stopping oral terbinafine when the nail “looks the same”: Terbinafine cures the infection at the matrix level within 12 weeks — but the infected nail must physically grow out over 9–12 months before you see a clear nail. Stopping treatment early because there is no visible change at 4 weeks is the most common cause of treatment failure.

Red Flags — When to See a Podiatrist Promptly

• More than two nails infected, or any nail with proximal involvement (cuticle area) — these require oral treatment and organism identification
• Nail changes in a diabetic patient — fungal nails increase the risk of tinea pedis and secondary bacterial cellulitis; prompt treatment is preventive medicine
• A dark longitudinal streak or band in any nail — requires evaluation to exclude subungual melanoma
• Home or OTC treatment for 3+ months with no improvement — the infection is too established for OTC agents
• Nail causing pain, pressure in shoes, or an ingrown edge — the nail mechanics need in-office management
• Proximal white/opaque nail discoloration appearing without prior injury — proximal subungual onychomycosis in a healthy adult should prompt HIV evaluation

Prevention — Stopping Recurrence

Recurrence rate after successful treatment is 20–25% within 3 years. Prevention protocol:

• Treat concurrent tinea pedis (athlete’s foot) aggressively — it is the most common source of reinfection
• Apply topical terbinafine cream to web spaces weekly as maintenance
• Use antifungal powder in shoes daily; rotate shoes (24-hour drying minimum)
• Wear sandals in public pools, locker rooms, gyms
• Weekly maintenance application of topical efinaconazole for 6–12 months after oral treatment completion
• Ensure proper shoe fitting — nail plate microtrauma from short shoes accelerates hyponychial penetration

Frequently Asked Questions

How long does it take to see results from terbinafine?

The 12-week oral course eradicates the fungus at the matrix level within that window — but because toenails grow only 1–2mm per month, the infected nail takes 9–12 months to fully grow out and be replaced by clear nail. You won’t see dramatic visual change in the first 3 months even with successful treatment. This is normal and expected — do not stop medication.

Is toenail fungus contagious?

Yes. Dermatophytes spread via direct contact with contaminated surfaces, shared towels, and footwear. During treatment, wear sandals around the house, disinfect shower floors with antifungal spray, and do not share nail care instruments. Family members who use shared showers are at elevated risk.

Can I get toenail fungus from a nail salon?

Yes — improperly sterilized tools and foot baths are documented transmission vectors. Bring your own instruments, verify autoclave sterilization between clients, and avoid nail cuticle cutting (creates a portal of entry).

Is oral terbinafine safe?

Serious liver injury from terbinafine is very rare — approximately 1 in 50,000 patients. We obtain baseline liver function tests before prescribing. For most healthy adults the benefit-to-risk ratio strongly favors treatment, particularly when untreated fungal nails pose secondary infection risk in a diabetic patient.

In-Office Toenail Fungus Treatment at Balance Foot & Ankle

We offer in-office nail PCR testing (same-visit or next-day results), prescription topical and oral antifungal management, Nd:YAG laser therapy, nail debridement to improve treatment penetration, and nail avulsion for total dystrophic cases. Most diagnostic visits are covered by insurance; laser therapy is a cash-pay service. Same-week appointments available.

Evidence and Sources

1. Gupta AK, Mays RR, Versteeg SG, et al. Efficacy of antifungal therapies for onychomycosis. J Eur Acad Dermatol Venereol. 2017;31(8):1382-1386.
2. Elewski BE, et al. Efinaconazole 10% solution in the treatment of toenail onychomycosis. J Am Acad Dermatol. 2013;68(4):600-608.
3. Lipner SR, Scher RK. Onychomycosis: clinical overview and diagnosis. J Am Acad Dermatol. 2019;80(4):835-851.
4. Gupta AK, et al. Recurrence of dermatophyte toenail onychomycosis. J Cutan Med Surg. 2013;17(Suppl 1):S9-S13.